Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Cubist Pharmaceuticals (Nasdaq: CBST) hit a new 52-week high Monday as it is currently trading at $49.94, above its previous 52-week high of $49.86 with 49,619 shares traded as of 9:50 a.m. ET. Average volume has been 760,600 shares over the past 30 days. Cubist has a market cap of $3.17 billion and is part of the health care sector and drugs industry. Shares are up 15.6% year to date as of the close of trading on Friday. Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products for various medical needs in the acute care environment in the United States. The company has a P/E ratio of 27.9, above the S&P 500 P/E ratio of 17.7.